0001415889-24-011058.txt : 20240417
0001415889-24-011058.hdr.sgml : 20240417
20240417192245
ACCESSION NUMBER: 0001415889-24-011058
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240416
FILED AS OF DATE: 20240417
DATE AS OF CHANGE: 20240417
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LaBarre Michael J.
CENTRAL INDEX KEY: 0001507174
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32335
FILM NUMBER: 24852458
MAIL ADDRESS:
STREET 1: 11388 SORRENTO VALLEY ROAD
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001159036
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 880488686
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12390 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 794-8889
MAIL ADDRESS:
STREET 1: 12390 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: HALOZYME THERAPEUTICS INC
DATE OF NAME CHANGE: 20040312
FORMER COMPANY:
FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC
DATE OF NAME CHANGE: 20010912
4
1
form4-04172024_110437.xml
X0508
4
2024-04-16
0001159036
HALOZYME THERAPEUTICS, INC.
HALO
0001507174
LaBarre Michael J.
C/O HALOZYME THERAPEUTICS, INC.
12390 EL CAMINO REAL
SAN DIEGO
CA
92130
false
true
false
false
SVP, CHIEF TECHNICAL OFFICER
1
Common Stock
2024-04-16
4
M
0
10000
8.11
A
178176
D
Common Stock
2024-04-16
4
S
0
10000
38.35
D
168176
D
Common Stock
2024-04-17
4
M
0
10000
8.11
A
178176
D
Common Stock
2024-04-17
4
S
0
10000
38.489
D
168176
D
Option to Purchase Common Stock
8.11
2024-04-16
4
M
0
10000
0
D
2026-02-03
Common Stock
10000
51715
D
Option to Purchase Common Stock
8.11
2024-04-17
4
M
0
10000
0
D
2026-02-03
Common Stock
10000
41715
D
The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.
Represents a weighted average sales price per share. These shares were sold at prices ranging from $38.275 to $38.785. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.
/s/ James R. Oehler, Attorney-in-Fact
2024-04-17